Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of … – Business Wire (press release)
|
Kite Announces Presentations on Its Lead CAR–T Therapy Development Program at the 2017 American Society of …
Business Wire (press release) Kite's lead product candidate, axicabtagene ciloleucel, previously known as KTE-C19, is an investigational therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed … |
